Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2015

01-04-2015 | Gastrointestinal Cancers (B Czito, Section Editor)

Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?

Authors: Xuguang Chen, Jennifer R. Eads, John B. Ammori, Aryavarta M. Kumar, Tithi Biswas, Jennifer A. Dorth

Published in: Current Oncology Reports | Issue 4/2015

Login to get access

Abstract

Gastric cancer is one of the most prevalent and deadliest forms of cancer worldwide. Even though neoadjuvant, perioperative, and adjuvant chemotherapy and/or radiation therapy may improve outcomes compared with surgery alone, the optimal combination of treatment modalities remains controversial. While European and North American trials established perioperative chemotherapy and adjuvant chemoradiation regimens for gastric cancer, Asian countries have focused on the use of adjuvant chemotherapy. This review summarizes results from contemporary randomized controlled trials and meta-analyses to elucidate the relative merits of each treatment approach.
Literature
1.
de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin N Am. 2013;42:219–40.CrossRef
2.
Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMed
3.
Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 2013;11:531–46.
4.
Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMed
5.
Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.CrossRefPubMed
6.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefPubMed
7.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMed
8.
9.•
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21. The ACCORD 07 study demonstrated a benefit of perioperative chemotherapy on the rate of curative resection and five-year overall survival for gastric cancer.
10.•
Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo (radio) therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;5:Cd008107. This Cochrane Review from 2013 demonstrated that perioperative chemotherapy is associated with a 19 % relative increase in 5-year overall survival (HR 0.81, 95 % CI 0.73-0.89), which translates to an absolute increase of 9 % in survival.
11.••
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. The CLASSIC trial (Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer) randomized patients to gastrectomy with D2 LND with or without adjuvant XELOX chemotherapy.
12.
Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMed
13.••
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33. After 10 years of follow up, there was a benefit in overall survival associated with adjuvant CRT (HR 1.32, 95 % CI 1.10-1.60, p = 0.0046).
14.••
Lee J, Lim Do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73. The ARTIST trial found that there was no difference in disease-free survival between patients who received adjuvant chemotherapy versus chemoradiation.  However, an unplanned subgroup analysis demonstrated that CRT improved relative disease-free survival by 32 % among 300 patients with positive lymph node involvement (HR 0.68, 95 % CI 0.47-0.99, p = 0.047). 
15.
Hartgrink HH, van de Velde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643–9.CrossRefPubMed
16.
Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin Oncol. 2010;28:5210–8.CrossRefPubMedCentralPubMed
17.
18.
Liao Y, Yang ZL, Peng JS, et al. Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. J Gastroenterol Hepatol. 2013;28:777–82.CrossRefPubMed
19.
Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg. 2013;30:119–29.CrossRefPubMed
20.
Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the CLASSIC trial. Ann Oncol. 2013;24:iv14.CrossRef
21.
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMed
22.
Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14: 113–123.
23.
Lee JH, Kim JG, Jung HK, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87–104.CrossRefPubMedCentralPubMed
24.
Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15:886–93.CrossRefPubMed
25.
Kang YK, Chang HM, Yook JH, et al. Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). Br J Cancer. 2013;108:1245–51.CrossRefPubMedCentralPubMed
26.
Bajetta E, Floriani I, Di Bartolomeo M, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014;25:1373–8.CrossRefPubMed
27.
Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.CrossRefPubMed
28.
Diaz-Nieto R, Orti-Rodriguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;9:CD008415.PubMed
29.
Markar SR, Karthikesalingam A, Jackson D, Hanna GB. Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and East. Ann Surg Oncol. 2013;20:2328–38.CrossRefPubMed
30.
Biffi R, Fazio N, Luca F, et al. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol. 2010;16:868–74.PubMedCentralPubMed
31.
Menges M, Schmidt C, Lindemann W, et al. Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate. J Cancer Res Clin Oncol. 2003;129:423–9.CrossRefPubMed
32.
Newman E, Marcus SG, Potmesil M, et al. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg. 2002;6:212–23. discussion 223.CrossRefPubMed
33.
Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol. 2002;12:187–95.CrossRefPubMed
34.•
Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8:1–11. The best characterization of patterns of failure after surgery alone comes from the University of Minnesota, where 109 gastric cancer patients underwent planned re-operations as part of a therapeutic regimen.
35.
Enzinger PC, Benedetti JK, Meyerhardt JA, et al. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007;245:426–34.CrossRefPubMedCentralPubMed
36.
Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107:2143–51.CrossRefPubMed
37.•
Ohri N, Garg MK, Aparo S, et al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:330–5. This meta-analysis compares adjuvant chemotherapy to CRT and demonstrates an improvement in local-regional control and disease-free survival, but not overall survival, associated with CRT. 
38.•
Shridhar R, Dombi GW, Weber J, et al. Adjuvant radiation therapy increases overall survival in node-positive gastric cancer patients with aggressive surgical resection and lymph node dissection: a SEER database analysis. Am J Clin Oncol. 2012;35:216–21. A SEER analysis of 11,630 gastric cancer patients who underwent surgery between 1990-2003 found that RT improved survival in all patients with positive lymph nodes, with a 5-year overall survival of 30 % with adjuvant RT versus 21 % without RT (p<0.0001).
39.
Fuchs CS, Tepper JE, Niedzwiecki D et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011; 29.
40.
Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–80.CrossRefPubMed
41.
Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953–8.CrossRefPubMed
42.
Kim TH, Park SR, Ryu KW, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84:e585–92.CrossRefPubMed
43.
Kwon HC, Kim MC, Kim KH, et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol. 2010;6:278–85.CrossRefPubMed
44.
Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104:361–6.CrossRefPubMed
45.
Huang YY, Yang Q, Zhou SW, et al. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 lymphadenectomy: a meta-analysis. PLoS ONE. 2013;8:e68939.CrossRefPubMedCentralPubMed
46.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMed
Metadata
Title
Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?
Authors
Xuguang Chen
Jennifer R. Eads
John B. Ammori
Aryavarta M. Kumar
Tithi Biswas
Jennifer A. Dorth
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Oncology Reports / Issue 4/2015
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-015-0442-4

Other articles of this Issue 4/2015

Current Oncology Reports 4/2015 Go to the issue

Gastrointestinal Cancers (BG Czito, Section Editor)

Contemporary Surgical Options for Metastatic Colorectal Cancer

Gynecologic Cancers (NS Reed, Section Editor)

Radical Surgery in Ovarian Cancer

Evolving Therapies (R Bukowski, Section Editor)

Activin Receptor Inhibitors—Dalantercept

Gynecologic Cancers (NS Reed, Section Editor)

Adenocarcinoma of the Cervix: Should We Treat It Differently?

Breast Cancer (B Overmoyer, Section Editor)

Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits